Literature DB >> 11944998

Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies.

F Nguyen1, Y Cherel, L Guigand, I Goubault-Leroux, M Wyers.   

Abstract

Golden retriever muscular dystrophy (GRMD), a degenerative myopathy due to the absence of dystrophin, is genetically homologous to human Duchenne muscular dystrophy (DMD). Spontaneous death of GRMD neonates within the first 2 weeks of life occurs frequently. This report describes the microscopical muscle lesions that developed in 12 GRMD puppies aged 1-8 days of age, and makes a comparison with three normal age-matched siblings and two older GRMD dogs. Immunohistochemical methods were used to confirm dystrophin deficiency in GRMD puppies. Muscle lesions were assessed on sections stained with haematoxylin-eosin-saffron, Gomori's trichrome and alizarin red S, and their severity was graded semi-quantitatively. Muscle fibre types were determined immunohistochemically on the basis of the pattern of expression of developmental, slow and fast isoforms of myosin. Muscle lesions in the GRMD puppies were characterized by massive necrosis, affecting most muscles of the proximal limbs, trunk and neck at birth. Lingual lesions began to develop in utero, and respiratory muscles underwent terminal diffuse necrosis resulting in death from acute respiratory failure. However, GRMD puppies do not invariably die in the neonatal period. Muscle in 2-month-old GRMD dogs showed signs of regeneration (immunohistochemical immaturity of muscle tissue), which suggested that all GRMD dogs suffer from massive post-natal myonecrosis, whether fatal or not. Muscle lesions in neonates consisted mainly of hyalinization, hypertrophy, calcification and necrosis, followed by regeneration. Such "phase I" lesions due to the absence of dystrophin are found in all species in which dystrophin deficiency has been described (human beings, dogs, cats and mice), whereas the endomysial fibrosis and myofibre atrophy found in 2-month-old GRMD dogs constituted "phase II" lesions, which are specific to GRMD and human DMD. Copyright Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11944998     DOI: 10.1053/jcpa.2001.0526

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  37 in total

Review 1.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

2.  Whole body skeletal muscle transduction in neonatal dogs with AAV-9.

Authors:  Yongping Yue; Jin-Hong Shin; Dongsheng Duan
Journal:  Methods Mol Biol       Date:  2011

Review 3.  The function of dog models in developing gene therapy strategies for human health.

Authors:  Keri L Nowend; Alison N Starr-Moss; Keith E Murphy
Journal:  Mamm Genome       Date:  2011-07-06       Impact factor: 2.957

Review 4.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

5.  Expiratory dysfunction in young dogs with golden retriever muscular dystrophy.

Authors:  Eleanor C Hawkins; Amanda K Bettis; Joe N Kornegay
Journal:  Neuromuscul Disord       Date:  2020-09-20       Impact factor: 4.296

Review 6.  Dystrophin-deficient large animal models: translational research and exon skipping.

Authors:  Xinran Yu; Bo Bao; Yusuke Echigoya; Toshifumi Yokota
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

Review 7.  The paradox of muscle hypertrophy in muscular dystrophy.

Authors:  Joe N Kornegay; Martin K Childers; Daniel J Bogan; Janet R Bogan; Peter Nghiem; Jiahui Wang; Zheng Fan; James F Howard; Scott J Schatzberg; Jennifer L Dow; Robert W Grange; Martin A Styner; Eric P Hoffman; Kathryn R Wagner
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-02       Impact factor: 1.784

8.  A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs.

Authors:  Yongping Yue; Arkasubhra Ghosh; Chun Long; Brian Bostick; Bruce F Smith; Joe N Kornegay; Dongsheng Duan
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

9.  RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice.

Authors:  Xiaodong Mu; Arvydas Usas; Ying Tang; Aiping Lu; Bing Wang; Kurt Weiss; Johnny Huard
Journal:  FASEB J       Date:  2013-05-23       Impact factor: 5.191

10.  Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.

Authors:  Caroline Le Guiner; Marie Montus; Laurent Servais; Yan Cherel; Virginie Francois; Jean-Laurent Thibaud; Claire Wary; Béatrice Matot; Thibaut Larcher; Lydie Guigand; Maeva Dutilleul; Claire Domenger; Marine Allais; Maud Beuvin; Amélie Moraux; Johanne Le Duff; Marie Devaux; Nicolas Jaulin; Mickaël Guilbaud; Virginie Latournerie; Philippe Veron; Sylvie Boutin; Christian Leborgne; Diana Desgue; Jack-Yves Deschamps; Sophie Moullec; Yves Fromes; Adeline Vulin; Richard H Smith; Nicolas Laroudie; Frédéric Barnay-Toutain; Christel Rivière; Stéphanie Bucher; Thanh-Hoa Le; Nicolas Delaunay; Mehdi Gasmi; Robert M Kotin; Gisèle Bonne; Oumeya Adjali; Carole Masurier; Jean-Yves Hogrel; Pierre Carlier; Philippe Moullier; Thomas Voit
Journal:  Mol Ther       Date:  2014-08-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.